Leveraging Dynamic Serum Uric Acid Trajectories for Risk Stratification in Hospitalized HFpEF Patients

Why It Matters

Identifying high‑risk HFpEF patients before discharge enables clinicians to apply nutritional or pharmacologic strategies aimed at lowering SUA, potentially reducing rehospitalization and mortality.

Key Takeaways

• Pre‑discharge SUA predicts MACE; admission SUA does not.
• Rising or persistently high SUA increases risk by ~60%.
• 5.6 mg/dL pre‑discharge cut‑off yields 84% sensitivity.
• Dynamic SUA adds prognostic value beyond standard clinical models.
• Targeted SUA reduction could become a therapeutic focus in HFpEF.

Pulse Analysis

Heart failure with preserved ejection fraction (HFpEF) accounts for roughly half of all heart‑failure cases and carries a steep readmission and mortality curve. Traditional risk tools rely on static clinical variables, yet the metabolic underpinnings of HFpEF—particularly insulin resistance, inflammation, and oxidative stress—remain under‑exploited for prognostication. Serum uric acid (SUA), a readily available marker of purine metabolism and oxidative burden, has emerged as a candidate biomarker, but most studies have examined a single measurement taken at admission, which may reflect transient hemodynamic shifts rather than sustained metabolic risk.

The new multicenter Chinese cohort of 4,164 acute HFpEF admissions provides robust evidence that the trajectory of SUA during hospitalization carries significant prognostic weight. Pre‑discharge SUA showed a strong, independent association with long‑term MACE (adjusted HR 1.23 per 1 mg/dL), while admission SUA did not. Patients whose SUA escalated from normal to high (N‑H) or stayed high (H‑H) experienced a 56‑61% higher hazard of adverse events compared with the normal‑normal group. A pre‑discharge threshold of 5.6 mg/dL delivered 84% sensitivity, and adding either the continuous pre‑discharge value or trajectory groups improved model fit beyond conventional risk factors, underscoring the incremental value of dynamic monitoring.

Clinically, these findings open a pathway for risk‑adapted management. Patients flagged by adverse SUA trajectories could receive intensified dietary counseling—low‑purine, low‑fructose regimens—and early initiation of agents known to lower uric acid, such as SGLT‑2 inhibitors or xanthine oxidase inhibitors, pending trial confirmation. Moreover, the study highlights the need for prospective trials to test whether modifying SUA trajectories translates into fewer readmissions and deaths. While the analysis is limited by its retrospective design and reliance on only two SUA points, it establishes a compelling case for incorporating dynamic metabolic biomarkers into HFpEF discharge planning.